Since its inception in 1994, the Center for Aids Research (CFAR) at Case Western Reserve University (CWRU) has been dedicated to coordinating a constantly-expanding spectrum of AIDS-related activities at CWRU and its primary affiliate, University Hospitals of Cleveland (UH). A productive relationship between the CFAR, the CWRU AIDS Clinical Trials Unit (ACTU) and the UH John T. Carey Special Immunology Unit (SIU) spearheads these efforts, ensuring that the two institutions fulfill their mandates as a center of academic excellence and a provider of patient care of the highest quality, respectively. CFAR development continues to benefit from co-operative and interactive ventures forged with additional CWRU centers in priority areas of mutual interest. These include the Cancer Research Center (CRC - AIDS-related malignancies), Skin Disease Research Center (SDRC - HHV-8 and Kaposi's sarcoma), Tuberculosis Research unit (TBRU - HIV/TB interactions) and Center for Medical Mycology (CMM - opportunistic fungal infections). This sustained effort over the last three years as witnessed a two-fold increase in CFAR membership drawn primarily from 12 departments of CWRU and UH), expansion of its present Funded Research Base (FRB) to approximately $13,000,000 in annual direct costs (covering all NIH-funded programs) and recruitment of clinical and basic research faculty. Organization expansion has involved addition of AIDS-Related Malignancies, Clinical Virology/Mycology and Behavioral Research Working Groups to those of International AIDS, Molecular Virology, Mycobacterial Research and Immunology. Finally, an expanded commitment to international AIDS programs has spawned a request to establish an international Clinical Coordination Facility (ICCF) in addition to those providing state-of-the- art technologies for Cytokine Measurement, Biosafety, Molecular Biology and Clinical Research. Collectively, these initiatives attest to successful development of the CWRU CFAR and provide the appropriate platform for its request for renewed funding.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-SCO-A (J1))
Program Officer
Plaeger, Susan F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786

Showing the most recent 10 out of 539 publications